Abstract
Ma et al recently reported in the World Journal of Diabetes that ferroptosis occurs in osteoblasts under high glucose conditions, reflecting diabetes pathology. This condition could be protected by the upregulation of the gene encoding polycytosine RNA-binding protein 1 (PCBP1). Additionally, Ma et al used a lentivirus infection system to express PCBP1. As the authors' method of administration can be improved in terms of stability and cost, we propose delivering PCBP1 to treat type 2 diabetic osteoporosis by encapsulating it in protein nanoparticles. First, PCBP1 is small and druggable. Second, intravenous injection can help deliver PCBP1 across the mucosa while avoiding acid and enzyme-catalyzed degradation. Furthermore, incorporating PCBP1 into nanoparticles prevents its interaction with water or oxygen and protects PCBP1's structure and activity. Notably, the safety of the protein materials and the industrialization techniques for large-scale production of protein nanoparticles must be comprehensively investigated before clinical application.